SRFL PHARMA PRIVATE LIMITED

In their own words

Ideation SRFL Pharma Private Limited has been incorporated with a vision to leverage India’s pharmaceutical manufacturing strength and address the rising global demand for affordable, quality medicines. We identified opportunities in international markets where regulatory pathways and supply chain inefficiencies limit access. To address this gap, our business model focuses on: (1) Product registration and supply, (2) Dossier licensing with supply, (3) Technology transfer for local manufacturing, and (4) Parallel trade to improve availability and pricing. Validation We validated this concept through market research across LATAM, EU, Middle East, and Asia, and by engaging with EU GMP / PIC/S approved manufacturers and licensed distributors. Early commitments from partners and initiation of registration processes confirmed the feasibility of our approach. The business model is compliant with international trade norms and has clear long-term potential. Traction While SRFL Pharma Private Limited is a newly incorporated entity, the founding team brings proven experience in global pharmaceutical exports, regulatory submissions, and dossier licensing. We have already initiated discussions and collaborations with manufacturers and distributors in multiple regions. Ongoing product registrations, dossier licensing agreements, and initial supply commitments reflect early traction and strong partner interest. Scaling Our future roadmap includes expanding product registrations across wider therapeutic areas, increasing dossier licensing agreements, and strengthening technology transfer partnerships in LATAM and Africa. We also plan to adopt digital tools for dossier and registration tracking to streamline global operations. Through these steps, SRFL Pharma Private Limited aims to establish itself as a specialized global pharma merchant-exporter, creating sustainable access to quality medicines worldwide.

Written by the company on its public Startup India profile. Not verified by us.